AFM
REGN icon

Armstrong Fleming & Moore’s Regeneron Pharmaceuticals REGN Stock Holding History

Armstrong Fleming & Moore’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-209
Closed -$220K – 101
2024
Q3 		$220K Hold
209
– – 0.13% 90
2024
Q2 		$220K Hold
209
– – 0.14% 86
2024
Q1 		$201K Buy
+209
New +$199K 0.14% 89

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armstrong Fleming & Moore's REGN Position: Q4 2024 in Review

Armstrong Fleming & Moore sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 209 shares — an estimated $220K sold.

Armstrong Fleming & Moore first reported a position in REGN in Q1 2024 and held it in 3 quarters. The position peaked at $220K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Armstrong Fleming & Moore reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Armstrong Fleming & Moore sold 209 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $220K.
  • Armstrong Fleming & Moore first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Armstrong Fleming & Moore's Regeneron Pharmaceuticals position peaked at $220K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Armstrong Fleming & Moore's 13F filing for Q4 2024, filed 5 Feb 2025.